Surmodics, Inc.

NasdaqGS:SRDX Stock Report

Market Cap: US$614.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surmodics Past Earnings Performance

Past criteria checks 0/6

Surmodics's earnings have been declining at an average annual rate of -28.3%, while the Medical Equipment industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 6.4% per year.

Key information

-28.30%

Earnings growth rate

-28.14%

EPS growth rate

Medical Equipment Industry Growth8.90%
Revenue growth rate6.42%
Return on equity-15.84%
Net Margin-14.59%
Last Earnings Update30 Jun 2025

Recent past performance updates

Recent updates

Analysis Article Jun 06

There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump

Surmodics, Inc. ( NASDAQ:SRDX ) shares have continued their recent momentum with a 29% gain in the last month alone...
Analysis Article May 30

Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?

Surmodics, Inc. ( NASDAQ:SRDX ), is not the largest company out there, but it received a lot of attention from a...
Analysis Article May 02

Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Amongst...
Analysis Article Sep 17

We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article Jun 26

News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts

Surmodics, Inc. ( NASDAQ:SRDX ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article Jun 22

An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Surmodics fair value estimate is US$41.07 Surmodics' US$30.10...
Analysis Article May 14

Is Surmodics (NASDAQ:SRDX) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Apr 17

Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher

Those holding Surmodics, Inc. ( NASDAQ:SRDX ) shares would be relieved that the share price has rebounded 36% in the...
Analysis Article Feb 03

Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package

The results at Surmodics, Inc. ( NASDAQ:SRDX ) have been quite disappointing recently and CEO Gary Maharaj bears some...
Analysis Article Jan 08

Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha Oct 17

Surmodics gets additional $125M in credit facility

Surmodics (NASDAQ:SRDX) has entered into a new, five-year credit agreement with MidCap Financial, comprised of up to $100M in term loans and a $25M revolving credit facility. The Company drew $25M on the term loan and $5M on the revolving credit facility at close. These proceeds were partially used to retire the company’s existing $25M revolving credit facility with Bridgewater Bank, of which $10M was outstanding. Upon closing, the company’s cash balance increased by $19.5M. Additional draws on the term loan may be made in $10M minimum increments, up to a total of $75M through December 31, 2024. A second tranche of up to $25M may be available through December 31, 2024 at MidCap’s option.  The credit agreement calls for interest-only payments on the term loan over the first four years, which can be extended to five years if certain criteria are met. The revolving credit facility matures in five years. Company expects total interest expense and fees under the credit agreement to be ~$3.4M in fiscal 2023.

Revenue & Expenses Breakdown

How Surmodics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SRDX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 25121-185238
31 Mar 25122-205338
31 Dec 24125-145338
30 Sep 24126-125338
30 Jun 24121-15247
31 Mar 24143145147
31 Dec 2313865134
30 Sep 23133-25247
30 Jun 23131-235351
31 Mar 23103-365351
31 Dec 22102-325163
30 Sep 22100-274751
30 Jun 2298-13420
31 Mar 2297-10370
31 Dec 211062340
30 Sep 2110543249
30 Jun 211042300
31 Mar 211077300
31 Dec 20951280
30 Sep 20951280
30 Jun 201038280
31 Mar 201017270
31 Dec 191006260
30 Sep 191008250
30 Jun 19922240
31 Mar 1990-2230
31 Dec 1887-2240
30 Sep 1881-4230
30 Jun 1878-2220
31 Mar 18741220
31 Dec 17720210
30 Sep 17734200
30 Jun 17716200
31 Mar 17739190
31 Dec 167310190
30 Sep 167110180
30 Jun 16719170
31 Mar 16679160
31 Dec 156411150
30 Sep 156212130
30 Jun 156013150
31 Mar 155913150
31 Dec 145812150

Quality Earnings: SRDX is currently unprofitable.

Growing Profit Margin: SRDX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SRDX is unprofitable, and losses have increased over the past 5 years at a rate of 28.3% per year.

Accelerating Growth: Unable to compare SRDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.2%).


Return on Equity

High ROE: SRDX has a negative Return on Equity (-15.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/20 22:44
End of Day Share Price 2025/11/18 00:00
Earnings2025/06/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Surmodics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Michael PetuskyBarrington Research Associates, Inc.
Jan WaldBenchmark Company